(Q33412969)

26 July 2017

0 references

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data (English)

1 reference

advanced head and neck cancer

26 July 2017

0 references

1 reference

1 reference

1 reference

1 reference

inferred from title

head and neck carcinoma

1 reference

3

Marc Buyse

0 references

Stefan Michiels

Stefan Michiels

1

0 references

Tomasz Burzykowski

Tomasz Burzykowski

4

0 references

Jean-Pierre Pignon

Jean-Pierre Pignon

12

0 references

Kie-Kian Ang

10

Kian K Ang

1 reference

26 July 2017

Aurélie Le Maître

2

1 reference

26 July 2017

Emilie Maillard

5

1 reference

26 July 2017

Jan Bogaerts

6

1 reference

26 July 2017

Jan B Vermorken

7

1 reference

26 July 2017

Wilfried Budach

8

1 reference

26 July 2017

Thomas F Pajak

9

1 reference

26 July 2017

Jean Bourhis

11

1 reference

26 July 2017

MARCH and MACH-NC Collaborative Groups

13

1 reference

26 July 2017

publication date

24 February 2009

1 reference

Lancet Oncology Commission

26 July 2017

published in

1 reference

26 July 2017

volume

10

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

341-350

1 reference

26 July 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

1 reference

7 January 2021

Chemoradiotherapy for locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Recent advances in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Individual patients' data meta-analyses in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Onc

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Combined bleomycin treatment and radiation therapy in squamous cell carcinoma of the head and neck region

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: a phase III clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer--preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Combined bleomycin and radiotherapy in oral cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Treatment of advanced head and neck cancer by means of radiation therapy plus chemotherapy — a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Treatment of advanced head and neck cancer: Multiple daily dose fractionated radiation therapy and sequential multimodal treatment approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Combined postoperative radiotherapy and Weekly Cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: results from two randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Simultaneous Chemoradiation in the Treatment of Advanced Head and Neck Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Feasibility of Non-Cisplatin-Based Induction Chemotherapy and Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiothera

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Patterns of failure in patients with locally advanced head and neck cancer treated postoperatively with irradiation or concomitant irradiation with Mitomycin C and Bleomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

[Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Intra-arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

A prospective study of preoperative chemotherapy and split-course irradiation for locally advanced or recurrent oral/pharyngeal squamous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Randomised EORTC Head and Neck Cooperative Group trial of preoperative intra-arterial chemotherapy in oral cavity and oropharynx carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Randomized study of adjuvant chemotherapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Induction chemotherapy in head and neck cancer: results of a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Induction chemotherapy in advanced head and neck cancer. Preliminary results of a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Induction chemotherapy in advanced head and neck tumors: results of two randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Combination chemotherapy as induction therapy for advanced resectable head and neck cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report of intergroup study 0034

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Perioperative chemotherapy in patients with oral cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

The validation of surrogate endpoints in meta-analyses of randomized experiments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Individual- and trial-level surrogacy in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Validation of surrogate end points in multiple randomized clinical trials with failure time end points

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Predicting where future means will lie based on the results of the current trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Progression-free survival is a surrogate for survival in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970023-3

7 January 2021

10.1016/S1470-2045(09)70023-3

Identifiers

DOI

1 reference

26 July 2017

1 reference